LATEST ANNOUNCEMENT

Micot Pharma's MT200605 Achieves Primary Endpoint in Phase II Trial, Novel Integrated Multi-stage Neuroprotection Mechanism to Be Presented at WSC 2026

HONG KONG, August 7, 2026 - (ACN Newswire) - On August 3, 2026, Shaanxi Micot Pharmaceutical Technology Co., Ltd. ("Micot Pharma"; 2335.HK) announced positive topline data from the Phase II clinical trial of MT200605, a proprietary drug candidate...